Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Cancer: early-phase trial registry
45 of 123 indexed Advanced Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #97 of 28,707 conditions by registered trial count.
123 US clinical trials · 45 currently recruiting · #97 of 28,707 conditions by registered trial count
Advanced Cancer: 123 US clinical trials tracked, 45 recruiting.
Advanced Cancer is the subject of 123 registered US clinical trials on ClinicalTrials.gov, 45 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 85 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 19 of these trials.
Enrollment posture brief
Registry condition advanced-cancer
OPEN 45 | RECR 37% | LATE 2 | EARLY 85 | RANK #97 | SPON 19
Volume-matched condition peers
Nearest open-share peer: Type 2 Diabetes (37% recruiting · 328 trials)
Advanced Cancer lists 45 open slots (37% of 123 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Cancer recruits in line with its size-band peers.
45 of 123 indexed trials (36.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Advanced Cancer research.
M.D. Anderson Cancer Center accounts for 19 of 123 trials (15.4%). 79 distinct sponsors appear on at least one study for this condition label.
-
Typical Advanced Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 123 trials that report a genuine target (sentinel values excluded). 65 of those (52.8%) plan for fewer than 100 participants.
-
Advanced Cancer research is mostly interventional.
112 interventional and 11 observational studies make up this index (91.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
123 total, page 1 of 3
Evaluating Disparities in Precision Oncology
Indiana University
NCT06081517
Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions
University of Chicago
NCT05166694
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
Alliance Foundation Trials
NCT06963723
BOLSTER: Learning New Skills to Thrive
Dana-Farber Cancer Institute
NCT06936878
AIMS Cancer Outcomes Study
Advanced Integrative Medical Science Institute
NCT04495790
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Apollomics
NCT03175224
Psychophysical Studies of Cancer Therapy Pain
M.D. Anderson Cancer Center
NCT00515060
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma
NCT04657068
A Study in Patients With Advanced Cancers
BiOneCure Therapeutics
NCT05320588
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
Jazz Pharmaceuticals
NCT05557045
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
I-Mab Biopharma US Limited
NCT04900818
Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients (CC N-of-1)
Cancer Commons
NCT07343024
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
NCT06242470
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Krystal Biotech
NCT06228326
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co.
NCT06707610
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Mirati Therapeutics
NCT05853575
Psilocybin Therapy in Advanced Cancer
NYU Langone Health
NCT05398484
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
OnKure
NCT06239467
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
NCT07432295
A Study of PHN-012 in Patients With Advanced Solid Tumors
Pheon Therapeutics
NCT07127874
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Riboscience
NCT05270213
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
CJ Bioscience
NCT05877430
Development of an Educational Patient Decision Aid (Treatments in Advanced Cancer - Decision Aid, TA-DA) to Promote Shared Decision Making for Third-line or Beyond Palliative Systemic Therapy
M.D. Anderson Cancer Center
NCT07009886
Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70)
Abramson Cancer Center at Penn Medicine
NCT06870617
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Incyclix Bio
NCT05735080
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
Biocity Biopharmaceutics Co.
NCT06548672
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Qurient Co.
NCT05394103
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma
NCT06362369
ALIGN for Older Adults With Cancer in SNFs
University of Colorado, Denver
NCT06616298
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
M.D. Anderson Cancer Center
NCT05663710
Electronic Patient Reporting of Symptoms and Unmet Needs to Connect Patients With Advanced Cancer to Palliative Care Services
Dartmouth-Hitchcock Medical Center
NCT07195513
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Angiex
NCT06440005
SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06389097
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT05004116
Development and Pilot Trial of Focused ACT (FACT) for Patients With Advanced Cancer
M.D. Anderson Cancer Center
NCT07105033
Pilot Trial of Spiritual Care Interventions for Patients With Cancer
Weill Medical College of Cornell University
NCT06811376
A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in Patients With Advanced Cancer: a Pilot Clinical Trial
M.D. Anderson Cancer Center
NCT07246954
Integrating Pain-CBT Into an mHealth Analgesic Support Intervention for Patients With Chronic Pain From Advanced Cancers
Dana-Farber Cancer Institute
NCT06722014
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Daiichi Sankyo
NCT06174987
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen
NCT05076760
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
M.D. Anderson Cancer Center
NCT07382544
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
M.D. Anderson Cancer Center
NCT06200155
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
Proviva Therapeutics
NCT06190886
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers
City of Hope Medical Center
NCT05204147
Psilocybin in Cancer Pain Study
Yvan Beaussant, MD, MSci
NCT06001749
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics
NCT03785249
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus
NCT03860272
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Eli Lilly and Company
NCT02711553
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
NCT01187199
Intrapleural Catheter Daily Versus Three Times a Week Drainage
M.D. Anderson Cancer Center
NCT00761618
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 71 |
| Phase 2 | 14 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Cancer page
123 registered trials, 45 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 45 Advanced Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Advanced Cancer trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Cancer condition card totals 123 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.